Q Fever Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute Q Fever, Chronic Q Fever), By Medication Type (Antibiotics, Antimalerial, Corticosteroids, Others), By End-Users (Hospitals, Clinics, Research Institutes), By Region, By Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 441.31 Million
CAGR (2026-2031)	5.21%
Fastest Growing Segment	Acute Q Fever
Largest Market	North America
Market Size (2031)	USD 598.53 Million

Market Overview

The Global Q Fever Market will grow from USD 441.31 Million in 2025 to USD 598.53 Million by 2031 at a 5.21% CAGR. The Global Q Fever Market encompasses the development and distribution of diagnostic assays, antibiotic therapies, and preventive vaccines aimed at managing infections caused by the bacterium Coxiella burnetii. Market expansion is primarily driven by rigorous government mandates for livestock screening and the strengthening of "One Health" initiatives that prioritize the surveillance of zoonotic diseases. Additionally, heightened occupational safety standards for high-risk sectors, such as veterinary medicine and meat processing, are compelling employers to adopt routine testing and prophylaxis protocols, thereby securing a steady demand for serological and molecular diagnostic tools.

However, the market confronts a significant impediment regarding the clinical underdiagnosis of the condition, as its non-specific symptoms often mimic influenza, leading to misidentification and delayed medical intervention. This diagnostic ambiguity obscures the actual disease burden and limits the addressable patient population for therapeutics. According to the 'European Food Safety Authority', in '2024', there were 805 confirmed human cases of Q fever reported across the European Union for the year 2023, representing an 11.5% increase compared to the previous year. This data highlights the persistent gap between disease prevalence and detection that challenges market scalability.

Key Market Drivers

Rising Global Prevalence of Zoonotic Q Fever Infections is fundamentally reshaping the market landscape by necessitating robust surveillance frameworks and rapid diagnostic deployment. As the pathogen Coxiella burnetii demonstrates resilience in environmental reservoirs, public health bodies are intensifying monitoring efforts to mitigate outbreaks that disrupt livestock economies and human health. This surge in identified cases is not merely a statistical artifact but a reflection of expanding endemic zones and improved detection capabilities across agricultural sectors. For instance, according to the Q-GAPS Consortium, July 2025, in the 'Q fever outbreak in Slovakia' report, authorities confirmed a significant resurgence with 11 human hospitalizations in the Prievidza district after decades of dormancy. Furthermore, according to the Australian Government Department of Health and Aged Care, October 2025, in the 'National Notifiable Diseases Surveillance System' report, the country recorded 951 Q fever notifications between October 2024 and October 2025, a figure substantially exceeding the five-year rolling average.

Growing Investment in Next-Generation Vaccine Research and Development is acting as a critical parallel driver, spurred by the limitations of existing prophylaxis which often requires cumbersome pre-screening to prevent hypersensitivity. The market is witnessing a pivot toward subunit and synthetic vaccine technologies designed to offer immunity without severe reactogenicity, thereby widening the potential for mass livestock and human immunization programs. Financial stakeholders and government entities are increasingly backing these initiatives to safeguard agricultural supply chains from the economic losses associated with reproductive failures in herds. This trend is evident in recent funding allocations; according to Sheep Central, February 2025, in the article 'Q Fever vaccine subsidy and research funding needed', the New South Wales Health Department allocated AUD 200,000 to the Australian Rickettsial Reference Laboratory to accelerate the development of a novel human Q fever vaccine. Such capital injections are pivotal for advancing candidates through clinical trials and overcoming the scalability barriers that have historically constrained the market.

Download Free Sample Report

Key Market Challenges

The clinical underdiagnosis of Q fever constitutes a primary obstacle to market growth by obscuring the true prevalence of the disease. As Coxiella burnetii infection frequently manifests with non-specific symptoms such as fever and fatigue, healthcare providers often misidentify the condition as common viral illnesses. This ambiguity leads to a failure in ordering necessary diagnostic tests, leaving a significant portion of the patient population undiagnosed. Consequently, the pharmaceutical and diagnostic sectors experience reduced revenue potential because the demand for antibiotic therapies and screening assays is directly contingent upon accurate clinical identification.

This persistent gap between actual incidence and reported figures limits the addressable market and disincentivizes investment in advanced countermeasures. When cases remain unrecorded, the perceived return on investment for new therapeutics diminishes. Underscoring this issue, according to the 'Australian Department of Health and Aged Care', in '2025', there were 951 notified cases of Q fever reported to the National Notifiable Diseases Surveillance System for the year ending October. This data highlights that while surveillance is active, the disconnect between symptoms and testing protocols continues to restrict the scalable expansion of the Global Q Fever Market.

Key Market Trends

The Transition to PCR-Based Molecular Diagnostics is fundamentally altering the Global Q Fever Market by replacing traditional serological methods with high-sensitivity genomic analysis. This technological shift is driven by the need for early-stage infection detection and precise quantification of bacterial loads, which antibody-based tests often fail to identify during the acute phase. The availability of advanced platforms is accelerating this transition, allowing laboratories to detect Coxiella burnetii with unprecedented accuracy across complex sample matrices. Underscoring this advancement, according to Qiagen N.V., June 2024, in the press release 'QIAGEN launches new QIAcuity digital PCR assays for microbial applications', the company introduced 35 new wet-lab tested microbial DNA detection assays, thereby expanding the accessibility of high-precision molecular testing tools suitable for infectious disease research and surveillance.

Simultaneously, the Standardization of Routine Bulk Tank Milk Monitoring is emerging as a critical trend in the veterinary sector, providing a scalable solution for herd-level disease management. This approach moves away from individual animal screening towards aggregate sampling of commingled milk, enabling cost-effective identification of shedding prevalence in dairy livestock reservoirs. This method has proven highly effective in revealing the cryptic burden of the disease in endemic agricultural regions. For instance, according to Ceva Animal Health, October 2024, in the 'Q Fever News Update Autumn 2024', an analysis of 900 bulk tank milk samples collected since 2020 revealed a cumulative positivity rate of 46%, demonstrating the widespread adoption and diagnostic utility of this bulk screening protocol for maintaining agricultural biosecurity.

Segmental Insights

The Acute Q Fever segment is currently experiencing rapid growth within the Global Q Fever Market. This expansion is primarily driven by the increasing prevalence of zoonotic transmission from livestock reservoirs, such as cattle and sheep, which facilitates the spread of Coxiella burnetii. Furthermore, advancements in diagnostic testing have improved the detection rates of initial flu-like symptoms that were historically underreported. The Centers for Disease Control and Prevention (CDC) indicates that acute cases consistently outnumber chronic infections, thereby sustaining high demand for early screening solutions and prompt therapeutic interventions to mitigate localized outbreaks.

Regional Insights

North America holds the leading position in the Global Q Fever Market, primarily driven by its advanced healthcare infrastructure and rigorous disease surveillance protocols. The region benefits from high clinical awareness and the widespread adoption of precise diagnostic technologies, such as polymerase chain reaction (PCR) and serological testing. Furthermore, the Centers for Disease Control and Prevention (CDC) designates Q fever as a nationally notifiable condition, ensuring consistent monitoring and data collection. These proactive government measures, combined with robust funding for zoonotic disease research, significantly bolster market growth in the region.

Recent Developments

• In April 2025, Cattle Australia, the national peak body for the grass-fed cattle industry, called for urgent government investment to accelerate the development and commercialization of a new single-dose Q fever vaccine. The organization emphasized the limitations of the current vaccination protocol, which requires pre-screening and multiple visits, arguing that a more accessible vaccine is critical for protecting the rural workforce. This market intervention highlighted the growing demand for improved prophylactic solutions and prompted discussions on funding final clinical trials for candidate vaccines currently under research.
• In February 2025, CSL Seqirus restored the normal supply of its Q-VAX vaccine and Q fever skin diagnostic tests following a period of national shortage in Australia. The company confirmed that it had successfully managed stock constraints that previously impacted the immunization of high-risk groups, such as abattoir workers and veterinarians. To support long-term market needs, CSL Seqirus also highlighted ongoing progress on a new, purpose-built manufacturing facility near Melbourne Airport, which is scheduled for completion in 2026 to secure the future production of this essential vaccine.
• In October 2024, Ceva Santé Animale announced the establishment of the European Q Fever Committee, a new "One Health" collaboration bringing together veterinary and medical experts to improve disease management. Alongside this initiative, the company released findings from a comprehensive survey of ruminant farmers across eight European countries, revealing significant gaps in disease awareness and biosecurity practices. The committee aims to use these insights to tailor educational campaigns and promote harmonized recommendations for the diagnosis, control, and prevention of Q fever in livestock, thereby reducing transmission risks to humans.
• In May 2024, the National Centre for Immunisation and Research and Surveillance, in collaboration with the University of Sydney, launched a large-scale research study to assess the safety and effectiveness of the Q-VAX vaccine in children. This initiative, which aims to potentially expand the eligibility for the only commercially available human Q fever vaccine, involves administering the vaccine to participants aged 10 to 14 years. The study addresses a critical gap in protecting younger populations at risk of infection from Coxiella burnetii, particularly those living on farms or in rural areas where the disease is prevalent.

Key Market Players

• Sun Pharmaceutical Industries Ltd.
• Abbott Laboratories Inc.
• Aurobindo Pharma Limited
• Pfizer Inc.
• Lupin Limited
• Bayer AG
• Novartis Pharmaceuticals Corporation
• GSK plc
• Merck & Co., Inc.
• Sanofi SA

By Type	By Medication Type	By End-Users	By Region
Acute Q Fever Chronic Q Fever	Antibiotics Antimalerial Corticosteroids Others	Hospitals Clinics Research Institutes	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Q Fever Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Q Fever Market, By Type:

• Acute Q Fever
• Chronic Q Fever

• Q Fever Market, By Medication Type:

• Antibiotics
• Antimalerial
• Corticosteroids
• Others

• Q Fever Market, By End-Users:

• Hospitals
• Clinics
• Research Institutes

• Q Fever Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE